Tiny Beverage Stock Bubbles Up 200% Growth

Author

Adam Garcia
April 02, 2025

​

An analytics firm is surging on double-digit revenue gains and an AI push, a medical device maker is up 10% on a strong revenue beat, and a beverage stock has nearly tripled itself after sealing a major U.S. distribution deal. Here’s what’s moving the markets right now.

Uranium Market (Sponsored)

On Behalf of Azincourt Energy Corp

A junior miner with high-grade uranium assets in Canada’s Athabasca Basin and Central Mineral Belt is making moves.

Plans are in motion, and the uranium market is heating up.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Futures 📈

What to Watch

Earnings:

  • RH [RH]: Aftermarket


  • Penguin Solutions, Inc. [PENG]: Aftermarket


  • Franklin Covey Company [FC]: Aftermarket


  • Resources Connection, Inc. [RGP]: Aftermarket


  • Bassett Furniture Industries, Incorporated [BSET]: Aftermarket


  • ClearSign Technologies Corporation [CLIR]: Aftermarket

Economic Reports:

  • ADP Employment [March]: 8:15 a.m.

  • Factory Orders [Feb]: 10:00 a.m.

  • Fed Governor Adriana Kugler will speak at 4:30 p.m.

Wellness Market (Sponsored)

Monster Beverage delivered the best-performing stock of the 21st century—rising a staggering 137,100% since 2000. That’s more than Amazon, Apple, or Tesla.

Now, one under-the-radar company could be positioned to follow in those footsteps.

With a breakthrough energy drink enhanced by patented nootropics, it’s targeting the $73B+ functional beverage market with a formula built for both performance and profits.

It’s already backed by Orangetheory co-founder David Long—and it’s still early.

Technology

Cognyte Closes Fiscal Year with Solid Gains, Eyes $392M in FY26 Revenue

Cognyte Software Ltd. (NASDAQ: CGNT) reported robust fourth-quarter and full-year results for the fiscal year ending January 31, 2025, driven by strong product demand and improving margins.

Shares of the investigative analytics software company are soaring 8% in premarket trade.

For the fourth quarter, Cognyte posted $94.5 million in revenue, a 13% year-over-year increase.

Adjusted EBITDA more than doubled to $9.3 million, while non-GAAP operating income rose to $6.0 million from just $1.0 million a year ago.

Although GAAP net loss narrowed to $0.2 million, the improvement marks significant operational progress.

Full-year revenue reached $350.6 million, up 12% from fiscal 2024. Adjusted EBITDA surged to $29.1 million—more than tripling the previous year’s figure.

The company also cut its net loss to $7.2 million, down from $11.6 million.

Cognyte closed the fiscal year with $113.1 million in cash and reported $46.8 million in operating cash flow for the year.

Looking ahead, the company projects fiscal 2026 revenue to reach $392 million and expects adjusted EBITDA of $43 million, indicating continued margin expansion.

Non-GAAP EPS is expected to hit $0.16.

CEO Elad Sharon says the company is benefiting from expanded client relationships and a focus on AI-driven solutions. CFO David Abadi added that profitability in 2026 is set to outpace revenue growth, driven by operating efficiency and recurring revenue gains.

Technology

BlackBerry Projects Up to $534M in FY26 Revenue After Cylance Sale and Cloud Pivot

BlackBerry Ltd. (NYSE: BB) reported better-than-expected financial results for its fourth quarter and fiscal year ending February 28, 2025, underscoring strong momentum across its key business segments.

In Q4, total revenue reached $141.7 million, supported by a robust 74% adjusted gross margin.

Operating earnings (EBITDA) stood at $21.1 million, beating internal forecasts.

The company’s QNX software unit contributed $65.8 million in sales, while its Secure Communications segment generated $67.3 million. Licensing revenue added $8.6 million to the total.

For the full year, BlackBerry reported $534.9 million in revenue with $84.2 million in adjusted EBITDA.

QNX revenue climbed 10% year-over-year to $236 million, while Secure Communications brought in $272.6 million. Licensing revenue totaled $26.3 million.

In a key strategic move, BlackBerry completed the sale of its cybersecurity unit, Cylance, to Arctic Wolf, netting an initial $80 million in cash and strengthening its balance sheet.

The company also forged new partnerships, including one with Microsoft to bring its QNX platform to Azure, and launched collaborations with major players like AMD, Intel, and Vector.

Looking ahead, BlackBerry forecasts Q1 FY2026 revenue between $107 million and $115 million. Full-year revenue is expected to range between $504 million and $534 million.

CEO John J. Giamatteo called the fiscal year “transformational,” citing steady performance across divisions and key milestones like the Cylance divestiture.

Uranium Sector (Sponsored)

On Behalf of Azincourt Energy Corp

Ninety percent of America’s uranium is imported. With the US scrambling to rebuild domestic supply, Canadian uranium companies are in prime position.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Medical Equipment

MedTech Growth Drives AngioDynamics Shares Up 10%

Shares of AngioDynamics (NASDAQ: ANGO) are soaring this morning on stronger-than-expected fiscal third-quarter results and increased full-year forecast.

The medical device maker’s stock is up more than 10% in premarket trading.

For the quarter ending February 28, the company’s adjusted earnings are $0.03 per share. This is significantly ahead of analysts’ projections, who anticipated a loss of $0.11 per share.

Revenue is at $72 million, exceeding the consensus estimate of $70.57 million.

The standout performer this quarter was AngioDynamics' MedTech division, which includes its Auryon atherectomy and thrombus management devices.

Sales in this segment surged 22.2% year-over-year to $31.3 million, contributing meaningfully to the company’s overall growth.

CEO Jim Clemmer credited the company’s strong topline growth and positive adjusted EBITDA for the quarter’s outperformance.

He also highlighted the continued success of AngioDynamics’ portfolio in driving consistent progress throughout the fiscal year.

Looking ahead, the company has raised its full-year 2025 revenue projection to a range of $285 million to $288 million, slightly up from the previous estimate.

It also narrowed its expected adjusted earnings loss to between $0.31 and $0.34 per share, an improvement from prior guidance.

The results and revised outlook reflect AngioDynamics' growing momentum in the medical technology space and its improved operating efficiency.

Movers and Shakers

Innovation Beverage Group Limited [IBG] - Last Close: $0.49

Innovation Beverage Group owns several bitters and premium beverage brands.

Its shares are up nearly 200% in premarket trading after announcing a major U.S. distribution deal with Republic National Distribution Company (RNDC), one of the country’s largest alcohol distributors, granting IBG access to key states including California and Michigan.

My Take: IBG is gaining traction fast in the global beverage market. This RNDC deal is a great chance for it to dominate the U.S. market. Watch this stock for growth-oriented upside.

Sunshine Biopharma Inc. [SBFM] - Last Close: $2.08

Sunshine Biopharma is a pharmaceutical manufacturer.

SBFM is making waves in premarket trading after posting impressive 2024 results, reporting $34.9 million in revenue—a 45% jump from last year.

My Take: Sunshine Biopharma is quickly evolving from a small-cap pharma to a serious contender in oncology and infectious disease. With strong sales momentum and credible scientific progress, it’s a stock worth keeping on your radar.

Sportsman's Warehouse Holdings, Inc. [SPWH] - Last Close: $0.97

Sportsman’s Warehouse is a go-to destination for outdoor gear, with a loyal customer base in hunting, fishing, and camping.

Shares are rising 40% in premarket trading after Sportsman’s posted better-than-expected same-store sales (down just 0.5% vs. 5% expected) and beat revenue forecasts.

My Take: Sportsman’s is showing signs of resilience with a niche market focus and solid fundamentals. While growth is slow, they seem to be headed for a broader recovery. Keep this stock on your wait and watch list.

Next-Gen Consumer Brands (Sponsored)

Monster Beverage shocked the market with a 137,100% return—beating Amazon, Apple, and even Tesla.

It’s not just another energy drink. This one’s infused with nootropics designed to support focus, clarity, and mood—exactly what today’s health-conscious consumers are demanding.

And the company behind it just brought on Orangetheory Fitness co-founder David Long as a board member. That kind of leadership rarely comes without serious conviction.

With a unique product, a booming category, and a proven industry heavyweight backing the mission, this could be the next beverage breakout story.

Everything Else

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.

*Standard message/carrier rates may apply.

Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.